Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.
Othman J, Tiong IS, O'Nions J, Dennis M, Mokretar K, Ivey A, Austin M, Latif AL, Amer M, Chan WY, Crawley C, Crolla F, Cross J, Dang R, Elliot J, Fong CY, Galli S, Gallipoli P, Hogan F, Kalkur P, Khan A, Krishnamurthy P, Laurie J, Loo S, Marshall S, Mehta P, Murthy V, Nagumantry S, Pillai S, Potter N, Sellar R, Taylor T, Zhao R, Russell NH, Wei AH, Dillon R. Othman J, et al. Among authors: elliot j. Blood. 2024 Jan 25;143(4):336-341. doi: 10.1182/blood.2023021579. Blood. 2024. PMID: 37647641
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery.
Wilson MR, Eyre TA, Martinez-Calle N, Ahearne M, Parsons KE, Preston G, Khwaja J, Schofield J, Elliot J, Mula Kh A, Shah N, Cheung CK, Timmins MA, Creasey T, Linton K, Smith J, Fox CP, Miall F, Cwynarski K, McKay P. Wilson MR, et al. Among authors: elliot j. Blood Adv. 2020 Aug 11;4(15):3586-3593. doi: 10.1182/bloodadvances.2020002421. Blood Adv. 2020. PMID: 32761231 Free PMC article.
Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis.
O'Reilly MA, Wilson W, Burns D, Kuhnl A, Seymour F, Uttenthal B, Besley C, Alajangi R, Creasey T, Paneesha S, Elliot J, Gonzalez Arias C, Iyengar S, Wilson MR, Delaney A, Rubio L, Lambert J, Begg K, Boyle S, Cheok KPL, Collins GP, Roddie C, Johnson R, Sanderson R. O'Reilly MA, et al. Among authors: elliot j. Hemasphere. 2024 Jun 13;8(6):e87. doi: 10.1002/hem3.87. eCollection 2024 Jun. Hemasphere. 2024. PMID: 38873532 Free PMC article.
Utility of 18F-FDG-PET/CT in lymphoblastic lymphoma.
Fox TA, Carpenter B, Taj M, Perisoglou M, Nicholson E, Castleton A, Elliot J, Uttenthal B, Wright C, Halsey R, Khwaja A, Grandage V, Mansour MR, Fielding AK, Hough R. Fox TA, et al. Among authors: elliot j. Leuk Lymphoma. 2021 Apr;62(4):1010-1012. doi: 10.1080/10428194.2020.1855346. Epub 2020 Dec 4. Leuk Lymphoma. 2021. PMID: 33275056 No abstract available.
A user-inspired mobility experience of the future: a qualitative investigation.
Peters J, Chen M, Huang K, Siero M, Elliot J, Bleakney A, Hsiao-Wecksler E, McDonagh D. Peters J, et al. Among authors: elliot j. Disabil Rehabil Assist Technol. 2024 Jul 3:1-10. doi: 10.1080/17483107.2024.2373303. Online ahead of print. Disabil Rehabil Assist Technol. 2024. PMID: 38958198
Phenotypic Clusters and Multimorbidity in Hypermobile Ehlers-Danlos Syndrome.
Petrucci T, Barclay SJ, Gensemer C, Morningstar J, Daylor V, Byerly K, Bistran E, Griggs M, Elliot JM, Kelechi T, Phillips S, Nichols M, Shapiro S, Patel S, Bouatia-Naji N, Norris RA. Petrucci T, et al. Among authors: elliot jm. Mayo Clin Proc Innov Qual Outcomes. 2024 May 15;8(3):253-262. doi: 10.1016/j.mayocpiqo.2024.04.001. eCollection 2024 Jun. Mayo Clin Proc Innov Qual Outcomes. 2024. PMID: 38779137 Free PMC article.
Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
Coutts SB, Ankolekar S, Appireddy R, Arenillas JF, Assis Z, Bailey P, Barber PA, Bazan R, Buck BH, Butcher KS, Camden MC, Campbell BCV, Casaubon LK, Catanese L, Chatterjee K, Choi PMC, Clarke B, Dowlatshahi D, Ferrari J, Field TS, Ganesh A, Ghia D, Goyal M, Greisenegger S, Halse O, Horn M, Hunter G, Imoukhuede O, Kelly PJ, Kennedy J, Kenney C, Kleinig TJ, Krishnan K, Lima F, Mandzia JL, Marko M, Martins SO, Medvedev G, Menon BK, Mishra SM, Molina C, Moussaddy A, Muir KW, Parsons MW, Penn AMW, Pille A, Pontes-Neto OM, Roffe C, Serena J, Simister R, Singh N, Spratt N, Strbian D, Tham CH, Wiggam MI, Williams DJ, Willmot MR, Wu T, Yu AYX, Zachariah G, Zafar A, Zerna C, Hill MD; TEMPO-2 investigators. Coutts SB, et al. Lancet. 2024 Jun 15;403(10444):2597-2605. doi: 10.1016/S0140-6736(24)00921-8. Epub 2024 May 17. Lancet. 2024. PMID: 38768626 Clinical Trial.
343 results